Evidence map›Paper›PMID 39575392›Full record

ArticleFrontiers in pharmacology2024

Xiuqing Zhu, Yuexin Li, Huan Luo, Yunxia Zhang, Zhenqing Zhang, Jinglai Li

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Plants (Basel, Switzerland) · 2025
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiuqing Zhu *Department of Pharmacy, The Affiliated Brain Hospital, Guangzhou Medical University, Guangzhou, China.
Yuexin Li *Guollence Pharmaceutical Technology Co., Ltd., Beijing, China.
Huan LuoGuollence Pharmaceutical Technology Co., Ltd., Beijing, China.
Yunxia ZhangGuollence Pharmaceutical Technology Co., Ltd., Beijing, China.
Zhenqing ZhangThe Key Laboratory of Drug Metabolism and Pharmacokinetics, Beijing Institute of Pharmacology and Toxicology, Beijing, China.
Jinglai LiGuollence Pharmaceutical Technology Co., Ltd., Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aim: Ammoxetine, a novel chiral serotonin and norepinephrine reuptake inhibitor, holds promise for major depressive disorder treatment. This study aimed to thoroughly investigate its preclinical drug metabolism and pharmacokinetics (DMPK) profiles. Methods: The preclinical DMPK profiles of ammoxetine were examined through Results: Assessment of blood-brain barrier penetration Conclusion: This study presents encouraging DMPK profiles of ammoxetine, backing its potential as a candidate compound for future clinical assessments.

Indexed as

ADMEammoxetineantidepressantdepressiondrug metabolism and pharmacokineticspreclinical pharmacokineticsserotonin and norepinephrine reuptake inhibitor

Identifiers

PMID39575392
PMCPMC11579541

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.